2023
Human Borrelia miyamotoi Infection in North America
Burde J, Bloch E, Kelly J, Krause P. Human Borrelia miyamotoi Infection in North America. Pathogens 2023, 12: 553. PMID: 37111439, PMCID: PMC10145171, DOI: 10.3390/pathogens12040553.Peer-Reviewed Original ResearchClinical manifestationsLyme diseasePersonal protective strategiesCommon clinical manifestationsBlood smear examinationFebrile illnessSmear examinationLaboratory confirmationEndemic areasInfectionProtective strategiesPreventive measuresDiseaseBodied ticksManifestationsProtective clothingBorreliaTicksArthralgiaMyalgiaNauseaComplicationsHeadacheCeftriaxoneFever
2022
Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States
Bloch E, Zhu X, Krause P, Patel E, Grabowski M, Goel R, Auwaerter P, Tobian A. Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States. Open Forum Infectious Diseases 2022, 9: ofac597. PMID: 36467296, PMCID: PMC9709699, DOI: 10.1093/ofid/ofac597.Peer-Reviewed Original ResearchNational Inpatient SampleLyme diseaseMale patientsAnnual incidenceHealth burdenLonger hospital stayMean hospital chargesHigher inpatient costsHospital-level variablesStratified systematic random sampleUS Census Bureau dataPerson/yearHospital stayPatient demographicsHospital admissionClinical outcomesHospital chargesInpatient costsInpatient hospitalizationInpatient SampleAdmission costsHospitalizationUS hospitalsDisease severitySystematic random sample
2021
Babesiosis
Chen T, Mamoun C, Krause P. Babesiosis. 2021, 1298-1304. DOI: 10.1093/med/9780190888367.003.0200.Peer-Reviewed Original ResearchB. microtiHard-bodied ticksHuman granulocytic anaplasmosisPowassan virusEtiologic agentIntraerythrocytic protozoaLyme diseaseBorrelia miyamotoiGranulocytic anaplasmosisBabesia infectionBorrelia burgdorferiDiseaseZoonotic diseaseB. duncaniAnaplasma phagocytophilumApicomplexa phylumInfectionMicrotiB. venatorumB. divergensBabesia sppBabesiosisIxodes scapularisPrimary vectorFeverClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
Krause PJ, Auwaerter PG, Bannuru RR, Branda JA, Falck-Ytter YT, Lantos PM, Lavergne V, Meissner HC, Osani MC, Rips JG, Sood SK, Vannier E, Vaysbrot EE, Wormser GP. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clinical Infectious Diseases 2021, 72: 185-189. PMID: 33501959, DOI: 10.1093/cid/ciab050.Peer-Reviewed Original ResearchConceptsInfectious Diseases SocietyDiseases SocietyInfectious disease specialistsClinical practice guidelinesPrimary care physiciansTransfusion medicine specialistsEvidence-based guidanceHuman granulocytic anaplasmosisRheumatology guidelinesDisease guidelinesCare physiciansDisease specialistsEmergency physiciansPractice guidelinesAmerican CollegeMedicine specialistsAmerican AcademyDisease controlLyme diseaseGranulocytic anaplasmosisDiagnosisPhysiciansBabesiosisGuidelinesTreatment
2020
644. Borrelia miyamotoi and Borrelia burgdorferi Seroprevalence in New England
Johnston D, Kelly J, Ledizet M, Lavoie N, Krause P. 644. Borrelia miyamotoi and Borrelia burgdorferi Seroprevalence in New England. Open Forum Infectious Diseases 2020, 7: s381-s381. PMCID: PMC7777872, DOI: 10.1093/ofid/ofaa439.838.Peer-Reviewed Original ResearchSerum samplesB. burgdorferi antibodiesMethods Serum samplesNon-endemic areasResidential zip codeResidential countyBackground diseasesBurgdorferi antibodiesMultiplex LuminexStudy participantsLyme diseaseSpirochetal pathogensBorrelia miyamotoiB. miyamotoiBorrelia burgdorferiB. burgdorferiCausative agentZip codesHuman exposureDiseaseAntibodiesMiyamotoiBurgdorferiIxodes scapularisBorrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors
Brummitt SI, Kjemtrup AM, Harvey DJ, Petersen JM, Sexton C, Replogle A, Packham AE, Bloch EM, Barbour AG, Krause PJ, Green V, Smith WA. Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors. PLOS ONE 2020, 15: e0243950. PMID: 33370341, PMCID: PMC7769429, DOI: 10.1371/journal.pone.0243950.Peer-Reviewed Original ResearchConceptsLyme diseaseBlood donorsB. miyamotoiB. burgdorferiEndemic countiesWestern blotBorrelia miyamotoiB. burgdorferi antibodiesAdult blood donorsBorrelia burgdorferiIgG Western blotBlood donor seraRisk of infectionELISA test systemBurgdorferi antibodiesDonor seraC6 ELISAClinical casesEquivocal samplesHuman casesDiseaseAntibodiesI. pacificus ticksMiyamotoiBurgdorferiClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease
Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton J, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases 2020, 72: e1-e48. PMID: 33417672, DOI: 10.1093/cid/ciaa1215.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInfectious Diseases SocietyClinical practice guidelinesLyme diseaseDiseases SocietyPractice guidelinesAmerican CollegeEvidence-based clinical practice guidelinesAmerican AcademyTick-borne rickettsial infectionInfectious disease specialistsPrimary care physiciansRheumatologic manifestationsCare physiciansErythema migransDisease specialistsMultidisciplinary panelEmergency physiciansFamily physiciansRickettsial infectionTick-borne pathogensDiseaseSeparate guidelinesPhysiciansDiagnosisPreventionClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease
Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton JJJ, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases 2020, 72: 1-8. PMID: 33483734, DOI: 10.1093/cid/ciab049.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInfectious Diseases SocietyClinical practice guidelinesLyme diseaseDiseases SocietyPractice guidelinesAmerican CollegeEvidence-based clinical practice guidelinesAmerican AcademyTick-borne rickettsial infectionInfectious disease specialistsPrimary care physiciansRheumatologic manifestationsCare physiciansErythema migransDisease specialistsMultidisciplinary panelEmergency physiciansFamily physiciansRickettsial infectionTick-borne pathogensDiseaseSeparate guidelinesPhysiciansDiagnosisPreventionClinical Practice Guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease
Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton JJJ, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Neurology 2020, 96: 262-273. PMID: 33257476, DOI: 10.1212/wnl.0000000000011151.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInfectious Diseases SocietyClinical practice guidelinesLyme diseaseDiseases SocietyPractice guidelinesAmerican CollegeEvidence-based clinical practice guidelinesAmerican AcademyTick-borne rickettsial infectionInfectious disease specialistsPrimary care physiciansRheumatologic manifestationsCare physiciansErythema migransDisease specialistsMultidisciplinary panelEmergency physiciansFamily physiciansRickettsial infectionTick-borne pathogensDiseaseSeparate guidelinesPhysiciansDiagnosisPreventionClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
Krause PJ, Auwaerter PG, Bannuru RR, Branda JA, Falck-Ytter YT, Lantos PM, Lavergne V, Meissner HC, Osani MC, Rips JG, Sood SK, Vannier E, Vaysbrot EE, Wormser GP. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clinical Infectious Diseases 2020, 72: e49-e64. PMID: 33252652, DOI: 10.1093/cid/ciaa1216.Peer-Reviewed Original ResearchConceptsInfectious Diseases SocietyDiseases SocietyInfectious disease specialistsClinical practice guidelinesPrimary care physiciansTransfusion medicine specialistsEvidence-based guidanceHuman granulocytic anaplasmosisRheumatology guidelinesDisease guidelinesCare physiciansDisease specialistsEmergency physiciansPractice guidelinesAmerican CollegeMedicine specialistsAmerican AcademyDisease controlLyme diseaseGranulocytic anaplasmosisDiagnosisPhysiciansBabesiosisGuidelinesTreatmentClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease
Lantos PM, Rumbaugh J, Bockenstedt LK, Falck‐Ytter Y, Aguero‐Rosenfeld M, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner H, Nigrovic LE, Nocton J, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis Care & Research 2020, 73: 1-9. PMID: 33251700, DOI: 10.1002/acr.24495.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease
Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner H, Nigrovic LE, Nocton J, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis & Rheumatology 2020, 73: 12-20. PMID: 33251716, DOI: 10.1002/art.41562.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2017
Human seroprevalence of Borrelia miyamotoi in Manitoba, Canada, in 2011-2014: a cross-sectional study
Kadkhoda K, Dumouchel C, Brancato J, Gretchen A, Krause PJ. Human seroprevalence of Borrelia miyamotoi in Manitoba, Canada, in 2011-2014: a cross-sectional study. CMAJ Open 2017, 5: e690-e693. PMID: 28882852, PMCID: PMC5621960, DOI: 10.9778/cmajo.20170070.Peer-Reviewed Original ResearchEnzyme-linked immunosorbent assayWestern blotLyme diseasePeptide enzyme-linked immunosorbent assayCross-sectional studyResidents of ManitobaTick-borne relapsing feverHuman seroprevalenceResidents of areasResidual seraRelapsing feverImmunosorbent assayBorrelia miyamotoiInitial reportSerumFeverInfectionDiseaseAntibodiesBlotBorreliaParticipantsSeronegativeSeropositiveHumans
2015
Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences
Diuk-Wasser MA, Vannier E, Krause PJ. Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences. Trends In Parasitology 2015, 32: 30-42. PMID: 26613664, PMCID: PMC4713283, DOI: 10.1016/j.pt.2015.09.008.Peer-Reviewed Original ResearchConceptsB. microtiDisease severityGreater disease severityEnzootic cycleCoinfected individualsTick-borne pathogenClinical consequencesTherapeutic strategiesLyme diseaseBabesia microtiHost factorsCoinfectionBorrelia burgdorferiB. burgdorferiIxodes ticksMicrotiReservoir hostsSeverityHuman pathogensBurgdorferiHuman babesiosis
Chen T, Mamoun C, Krause P. Human babesiosis. 2015, 1295-1301. DOI: 10.1017/cbo9781139855952.226.Peer-Reviewed Original ResearchHuman babesiosisB. microtiB. microti infectionHard-bodied ticksClustering of casesHuman granulocytic anaplasmosisAcute illnessRenal failureBlood transfusionMicroti infectionCommon causeBabesia duncaniEndemic areasEtiologic agentHuman infectionsHuman B. microti infectionIntraerythrocytic protozoaLyme diseaseBabesia microtiBabesia speciesDiseaseGranulocytic anaplasmosisBabesia infectionIntraerythrocytic parasitesInfectionBorrelia miyamotoi infection in nature and in humans
Krause PJ, Fish D, Narasimhan S, Barbour AG. Borrelia miyamotoi infection in nature and in humans. Clinical Microbiology And Infection 2015, 21: 631-639. PMID: 25700888, PMCID: PMC4470780, DOI: 10.1016/j.cmi.2015.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsB. miyamotoi infectionMiyamotoi infectionClinical manifestationsB. miyamotoiLyme diseaseBorrelia miyamotoi infectionAcute febrile illnessCommon clinical manifestationsBlood smear examinationPublic health importanceHuman granulocytic anaplasmosisFever group spirochetesFebrile illnessAntibiotic therapyDisease groupEtiologic diagnosisSevere diseaseSmear examinationIxodes persulcatus ticksHealth importanceInfectionHuman casesGranulocytic anaplasmosisBorrelia miyamotoiDisease
2014
Blood transfusion transmission of the tick‐borne relapsing fever spirochete Borrelia miyamotoi in mice
Krause PJ, Hendrickson JE, Steeves TK, Fish D. Blood transfusion transmission of the tick‐borne relapsing fever spirochete Borrelia miyamotoi in mice. Transfusion 2014, 55: 593-597. PMID: 25251880, DOI: 10.1111/trf.12879.Peer-Reviewed Original ResearchConceptsTransfusion transmissionRed blood cellsBorrelia miyamotoiBlood transfusion transmissionMurine transfusion modelFever spirochete Borrelia miyamotoiSpirochete clearanceRecipient bloodC57BL/6 miceMouse recipientsTransfusion modelMouse modelTransfusionMurine bloodHuman infectionsWet mountLyme diseaseStudy designBlood cellsMiceMiyamotoiSpirochetemiaFever spirochetesBloodBodied ticksBorrelia miyamotoi sensu lato Seroreactivity and Seroprevalence in the Northeastern United States - Volume 20, Number 7—July 2014 - Emerging Infectious Diseases journal - CDC
Krause PJ, Narasimhan S, Wormser GP, Barbour AG, Platonov AE, Brancato J, Lepore T, Dardick K, Mamula M, Rollend L, Steeves TK, Diuk-Wasser M, Usmani-Brown S, Williamson P, Sarksyan DS, Fikrig E, Fish D, . Borrelia miyamotoi sensu lato Seroreactivity and Seroprevalence in the Northeastern United States - Volume 20, Number 7—July 2014 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2014, 20: 1183-1190. PMID: 24960072, PMCID: PMC4073859, DOI: 10.3201/eid2007.131587.Peer-Reviewed Original ResearchConceptsB. burgdorferiInfectious Diseases journal - CDCSeroprevalence of IgGB. burgdorferi antigensLyme disease endemic areaDisease-endemic areasAntibody testingHealthy personsLyme diseaseSerum samplesSeroprevalenceBurgdorferiInfectionSame tickUnited StatesSensu latoArea residentsPersonsBorrelia spSeroreactivityIgGAntigenDiseaseSerumMonitoring Human Babesiosis Emergence through Vector Surveillance New England, USA - Volume 20, Number 2—February 2014 - Emerging Infectious Diseases journal - CDC
Diuk-Wasser MA, Liu Y, Steeves TK, Folsom-O'Keefe C, Dardick KR, Lepore T, Bent SJ, Usmani-Brown S, Telford SR, Fish D, Krause PJ. Monitoring Human Babesiosis Emergence through Vector Surveillance New England, USA - Volume 20, Number 2—February 2014 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2014, 20: 225-231. PMID: 24447577, PMCID: PMC3901474, DOI: 10.3201/eid2002.130644.Peer-Reviewed Original ResearchConceptsHuman babesiosisInfectious Diseases journal - CDCProtozoan Babesia microtiDisease-endemic areasTick-borne diseaseBabesiosis-endemic areasSame tick vectorInfection rateInfection ratioTick infection ratesLyme diseaseBabesia microtiHuman casesDiseaseDisease expansionBabesiosisReservoir hostsTick vectorHuman diseasesSurveillanceClose association
2011
Long-Term Lyme Disease Antibiotic Therapy Beliefs Among New England Residents
Macauda MM, Erickson P, Miller J, Mann P, Closter L, Krause PJ. Long-Term Lyme Disease Antibiotic Therapy Beliefs Among New England Residents. Vector-Borne And Zoonotic Diseases 2011, 11: 857-862. PMID: 21417921, DOI: 10.1089/vbz.2010.0116.Peer-Reviewed Original ResearchConceptsLyme diseasePersistent symptomsAntibiotic treatmentEffective doctor-patient communicationAntibiotic therapy regimensInfectious Diseases SocietyLong-term treatmentBorrelia burgdorferi infectionDoctor-patient communicationFederal health agenciesDiseases SocietyAppropriate therapyTherapy regimensAntimicrobial therapyBurgdorferi infectionHealthcare workersMost physiciansStandard diagnosisDisease controlDiseasePatientsHealth agenciesSymptomsPhysiciansMedical societies